# A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

> **NCT04460183** · PHASE2,PHASE3 · COMPLETED · sponsor: **Thirty Respiratory Limited** · enrollment: 19 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** RESP301, a Nitric Oxide generating solution
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04460183
- **Lead sponsor:** Thirty Respiratory Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2021-04-24
- **Final completion:** 2021-05-21
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460183, "A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04460183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*